Endonovo Therapeutics Inc (OTCMKTS:ENDV) Has Some Catalysts On The Cards

Having slowly devalued throughout the latter half of 2016 and into the first quarter of this year, Endonovo Therapeutics Inc (OTCMKTS:ENDV) is staging something of a recovery. The company went for $0.012 at the beginning of March, down nearly 95% on its July 2016 pricing. At last close, however, it had jumped to $0.037 – a 210% run for March to date.Why is it running up?At first glance, there's no obvious driver. This is a company that hasn’t put out an update in around three months, and hasn’t filed anything since early February, and that was a convertible designation. We think it might not be about what's happened, but about what's just around the corner. There are a couple of key catalyst set to hit press, and the value run up could be traders loading up ahead of any potential news driven impact.For those new to this company, Endonovo is a young biotech with two lead programs. The first is rooted in what it calls its Cytotronics platform and it's designed to make the drug development process more efficient. The concept behind it is pretty simple. Right now, it costs around $15 million (average, of course) to conduct a phase I study. Only 10% of those conducted move into phase II. That's nine out of ten companies spending money on a phase I wasting it. A large portion of the phase I failures are rooted in tolerability (after all, that's what these studies are generally set up to measure). The Cytotronics platform is essentially a stem cell growing platform, that allows drug developers to create cell cultures that mimic in vivo cells very closely, and both last a long time (180 days) and are quick to produce. The developer in question can then use these cultures to test for any potential toxicity issues, before wasting money on a phase I trial.The second program, and one that underpins one of the two catalysts we're focusing on here, is a non invasive electroceutical platform called Immunotronics. The idea with this one is that the lead assets in the space are invasive (implants, etc.) and expensive (stem cells, gene therapies) and, with Immunotronics, Endonovo can overcome both these drawbacks. It's basically a non implantable and non invasive device that uses electronic pulses to treat inflammatory and cardiovascular conditions.It's really early days for both of these products, and this company is one of those biotechs that limps along from financing to financing, diluting holders and not really bringing too much in the way of fundamental developments to the plate. That's why it's lost so much on its PPS over the last twelve months. This could be about to change, however. The company kicked off the first of a raft of preclinical studies of the Immunotronics platform at the end of last year, to evaluate the effect of the device on cardiac function, post-MI remodeling, and infarct size, as well as angiogenesis (the development of new blood vessels). These studies are really the first thing that we’ve been able to say can start producing actionable catalysts, and the one that kicked off at the end of last year is about to close out. And that's our first catalyst. Management stated here that it will wrap up during first quarter 2017, meaning we've got a couple of weeks before the news hits press. If it comes out as indicative of efficacy, there's a real kick on the cards in Endonovo's market cap.Beyond this, and as our second catalyst, we're looking to an uplisting. The company announced mid to late last year that it was preparing to uplist to a national exchange, and that its target was to get this done during the first half of 2017. In the wake of a data driven boost, then, we think we'll see an application during the second quarter, and a run on the listing securing.Of course, at its current price, shareholders are probably going to have to shoulder a reverse split to facilitate any listing, but the benefits of a national listing will likely outweigh any negative impact of an RS, at least longer term.We will be updating our subscribers as soon as we know more. For the latest updates on ENDV, sign up below!Disclosure: We have no position in ENDV and have not been compensated for this article.